SCHEMBL3884147

SCHEMBL3884147

Cc1ccc(NC(=O)C(=O)c2c(-c3ccccc3)cc3c(C)cccn23)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 8/20 0.49
LMNA P02545 4/20 0.49
HTT P42858 4/20 0.49
MAPT P10636 5/20 0.47
ALDH1A1 P00352 5/20 0.47
THRB P10828 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.43
RAB9A P51151 6/20 0.42
NPC1 O15118 4/20 0.42
RXFP1 Q9HBX9 1/20 0.41
PKM P14618 1/20 0.40
NFKB1 P19838 1/20 0.40
NFKB2 Q00653 1/20 0.40
RELA Q04206 1/20 0.40
PTPN1 P18031 1/20 0.40
PTPN11 Q06124 1/20 0.40
KDM4E B2RXH2 1/20 0.39
GAA P10253 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1646260 0.89 LMNA (0.47) SMN1; SMN2LMNAHTTMAPTALDH1A1
SCHEMBL3884080 0.87 LMNA (0.44) SMN1; SMN2LMNAHTTMAPTALDH1A1
SCHEMBL1645379 0.84 THRB (0.65) SMN1; SMN2LMNAHTTMAPTALDH1A1
SCHEMBL1645267 0.83 PDE4A (0.47) SMN1; SMN2LMNAHTTMAPTALDH1A1
SCHEMBL1645232 0.81 SMN1; SMN2 (0.52) SMN1; SMN2LMNAHTTMAPTALDH1A1
SCHEMBL3896628 0.79 SMN1; SMN2 (0.46) SMN1; SMN2LMNAHTTMAPTALDH1A1
SCHEMBL1645256 0.79 LMNA (0.51) SMN1; SMN2LMNAHTTMAPTALDH1A1
SCHEMBL3898847 0.78 POLB (0.46) SMN1; SMN2LMNAHTTMAPTALDH1A1
SCHEMBL3886748 0.76 SMN1; SMN2 (0.49) SMN1; SMN2LMNAHTTMAPTALDH1A1
SCHEMBL1644339 0.76 SMN1; SMN2 (0.55) SMN1; SMN2LMNAHTTMAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8486962-B2 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2013-07-16 US disclosed
EP-1888063-B1 ANTIFUNGAL AGENTS F2G LTD (GB) 2009-01-14 EP disclosed
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus F2G LTD. (GB) 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161302-A1 N-(2-Methoxy-phenyl)-2-oxo-2-(2-phenyl-indolizin-3-yl)-acetamide; antifungal agents; inhibiting Aspergillus NAT1, CYP1A2, CYP51A1 SMN1; SMN2 3501/4885LMNA 2694/4885HTT 3105/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.